Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Defina, Marzia
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. [electronic resource] - Cancer Nov 2012 - 5265-9 p. digital
Publication Type: Journal Article
1097-0142
10.1002/cncr.27506 doi
Adult
Aged
Aged, 80 and over
Antigens, CD34--metabolism
Antineoplastic Agents--therapeutic use
Bone Marrow Cells--pathology
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Leukemia, Myeloid, Chronic-Phase--drug therapy
Male
Middle Aged
Neoplastic Stem Cells--pathology
Protein Kinase Inhibitors--therapeutic use
Pyrimidines--therapeutic use
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. [electronic resource] - Cancer Nov 2012 - 5265-9 p. digital
Publication Type: Journal Article
1097-0142
10.1002/cncr.27506 doi
Adult
Aged
Aged, 80 and over
Antigens, CD34--metabolism
Antineoplastic Agents--therapeutic use
Bone Marrow Cells--pathology
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Leukemia, Myeloid, Chronic-Phase--drug therapy
Male
Middle Aged
Neoplastic Stem Cells--pathology
Protein Kinase Inhibitors--therapeutic use
Pyrimidines--therapeutic use